Schneider, 2005, [21] [94]	Tinnitus associated with AD	Randomized, placebo- controlled, double-blind, parallel-group, multicenter	513 with tinnitus and AD (169 received GBE 120mg, 170 received GBE 240 mg, and 174 received placebo).	Mean age 78 years	120 mg EGb 761/ day or 240 mg EGb 761/day (vs. placebo) for 26 weeks, no follow-up	Secondary outcome variable: change in 11-point box scales for the rating of presence and severity of dizziness and tinnitus from baseline.	Dizziness: Mean reduction difference in dizziness severity in favor of placebo treated patients compared to GBE treated patients (+0.47 [95% CI: −1.18, +2.12]) Tinnitus: Mean reduction difference in tinnitus severity in favor of GBE treated patients compared to placebo was statistically meaningful (−1.84 [95% CI: −3.00, −0.68]).
Drew and Davies, 2001, [77]	Tinnitus	Double-blind, placebo- controlled	1,121 (559 to active treatment and 562 to placebo)	Mean: 53 years	3 × 50 mg = 150 mg LI 1370/day (vs. placebo) for 12 weeks, 2 weeks follow-up	Participants’ assessment of tinnitus before, during, and after treatment recorded in a questionnaire (changes in loudness were rated on a 6-point scale and changes in how troublesome were rated on a 5-point scale).	No significant differences between the groups.
Halama, 1988, [71] [article in German]	Light to moderate cerebrovascular insufficiency	Randomized, double-blind, placebo- controlled	40; i.d.	>55 years (no upper limit)	3 × 40 mg = 120 mg EGb 761/day (vs. placebo) for 12 weeks, no information on follow-up	Change in SCAG from baseline.	In the treatment group, SCAG score decreased by an average of 9 points, but remained unchanged in the placebo group (p < 0.005); superior effects of GBE were demonstrated for headache and tinnitus.
Meyer, 1986, [76] [article in French]	Tinnitus	Multicenter, randomized, double-blind, placebo- controlled	103 with tinnitus	Mean age treatment group 50.97 years vs. placebo group 49.76 years	4 ml containing 160 mg EGb 761/day (vs. placebo) for 12 weeks, no follow-up	Overall effects were assessed using a 6-point ordinal scale and the symptoms a 4-point ordinal scale.	Better efficacy for GBE vs. placebo irrespective of initial description or prognostic factors; p = 0.05: a statistically significant difference in favor of the group treated with GBE, the evolution of which was much faster (unilateral test p = 0.03); duration until disappearance or significant improvement in 50% of patients was 70 days in the GBE group and 119 days in the placebo group; change in intensity appeared to be statistically better in the GBE group (unilateral test p = 0.03); and change in nuisance (unilateral test p = 0.08).